The FDA has not cleared any stem cell therapy for CRPS. The condition itself is recognised, but cellular treatments sit outside approved interventions. Internationally, regulatory pathways vary: some European clinics operate under Advanced Therapy Medicinal Product (ATMP) frameworks for exploratory use; others lack formal clearance. Patients should verify the regulatory status of any clinic before treatment.
Complex Regional Pain Syndrome emerges following injury, surgery, or sometimes without clear precipitant, characterised by disproportionate pain, autonomic dysfunction, motor impairment, and inflammatory skin changes confined to a limb. Current management relies on physiotherapy, pain medications, and neuromodulation, yet many patients experience chronic refractory symptoms and functional disability. Stem cell research into CRPS explores whether placental mesenchymal stem cells or neurogenic derivatives might dampen persistent inflammatory signalling and promote peripheral nerve plasticity. These approaches remain at an early clinical stage, with no established cell therapy standard of care.
Am I a candidate? → · Complex Regional Pain Syndrome: full overview → · Complex Regional Pain Syndrome cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite